Latest MicroRNA Stories
Researchers at Duke University Medical Center may finally have discovered why people with sickle cell disease get milder cases of malaria than individuals who have normal red blood cells. In a finding that has eluded scientists for years, Duke researchers discovered that genetic material in red blood cells may help alter parasite activity via a novel mechanism that alters parasite gene regulation. "One of the most interesting findings in our study is that the human microRNA (very small...
LA JOLLA, Calif., Aug. 15, 2012 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered into a collaboration with Biogen Idec (NASDAQ: BIIB) to identify microRNAs as biomarkers for multiple sclerosis (MS). Under the transaction, Biogen Idec will make an investment in Regulus in addition to upfront and milestone payments. The key objective of the...
LA JOLLA, Calif., Aug. 14, 2012 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered into a strategic alliance with AstraZeneca to discover, develop, and commercialize microRNA therapeutics for three exclusive targets which are currently in pre-clinical development. These targets are focused on cardiovascular and metabolic diseases and...
MOUNTAIN VIEW, Calif., Aug. 13, 2012 /PRNewswire/ -- Based on its recent analysis of the next-generation diagnostics market, Frost & Sullivan recognizes Rosetta Genomics with the 2012 North American Frost & Sullivan Award for Entrepreneurial Company of the Year. Rosetta Genomics successfully competes in a concentrated market and achieved significant product adoption, while bringing value to both patients and investors. A recent Frost & Sullivan analysis on the...
PHILADELPHIA and REHOVOT, Israel, Aug. 13, 2012 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that Frost & Sullivan has recognized Rosetta Genomics with the 2012 North American Next Generation Diagnostics Entrepreneurial Company of the Year Award. A recent Frost & Sullivan analysis on the United States cancer biomarkers market confirmed the growing credibility of clinical...
Breast cancers that depend on the hormones estrogen and progesterone are susceptible to treatments targeting these hormones. Take away this dependence and you lose a valuable treatment option. A University of Colorado Cancer Center study published as a featured article in the journal Oncogene shows how progesterone does just this – by suppressing a key microRNA, progestins return breast cancer cells to a stem-cell-like state in which they haven’t yet differentiated, and are thus more...
ALBANY, New York, August 6, 2012 /PRNewswire/ -- New Report Added in ResearchMoz Reports Database "MicroRNAs and Exosomes Market Report 2012 [http://www.researchmoz.us/micrornas-and-exosomes-market-report-2012-report.html ]" This is the latest and most up-to-date Market Report from Select Biosciences addressing the microRNA and Exosomes markets as they are evolving. In this report, we focus upon the microRNA research marketplace from the perspective of the...
PHILADELPHIA and REHOVOT, Israel, July 24, 2012 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic assays, announced today that it has entered into a co-marketing agreement for its miRview(®) mets(2) assay for the accurate identification of the tumor of origin in Cancers of Unknown or Uncertain Primary ("CUP") with Precision Therapeutics Inc., a life science company known for its expertise in the science of...
SANTA CRUZ, Calif., July 24, 2012 /PRNewswire/ -- SomaGenics, Inc., a biotechnology company specializing in RNA-based technologies, announced the publication of a study reporting the mechanism of action of its sshRNAs, the class of molecules that forms the basis of the company's therapeutic platform. sshRNAs are small synthetic stem-loop (or hairpin) RNAs that the company's researchers have shown to be highly potent in knocking down target RNAs through an RNA interference (RNAi)...
MicroRNAs (miRNAs) are endogenously encoded RNAs that regulate the stability or translation of mRNA molecules, and emerging research suggests that they have diverse roles in normal physiology and disease. In this issue, two groups investigated the role of the predominant liver miRNA, miR-122. Ann-Ping Tsou and colleagues from National Yang-Ming University in Taiwan, and a team led by Kalpana Ghoshal, from Ohio State University generated mouse models of MiR-122 loss of function, and determined...
